New pill could tame ulcerative colitis without needles
NCT ID NCT07374471
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral biologic called MB-001 in 100 adults with moderate-to-severe ulcerative colitis. Participants take either MB-001 or a placebo daily for 12 weeks, then may continue in an open-label phase. Researchers will check for side effects and measure improvements in symptoms, colon inflammation, and lab results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MB-001 (an oral biologic)
What this could lead to
If successful, this could provide a new oral treatment option for people with moderate-to-severe ulcerative colitis, potentially reducing symptoms and improving quality of life.
What could go wrong
This is an early-phase trial with only 100 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 3001
RECRUITINGChisinau, Moldova